Article Versions Notes

Sommerburg O, Hämmerling S, Schneider SP, Okun J, Langhans C-D, Leutz-Schmidt P, Wielpütz MO, Siems W, Gräber SY, Mall MA, et al. CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. Antioxidants. 2021; 10(3):483. https://doi.org/10.3390/antiox10030483

Sommerburg, Olaf, Susanne Hämmerling, S. Philipp Schneider, Jürgen Okun, Claus-Dieter Langhans, Patricia Leutz-Schmidt, Mark O. Wielpütz, Werner Siems, Simon Y. Gräber, Marcus A. Mall, and et al. 2021. "CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis" Antioxidants 10, no. 3: 483. https://doi.org/10.3390/antiox10030483

Sommerburg, O., Hämmerling, S., Schneider, S. P., Okun, J., Langhans, C.-D., Leutz-Schmidt, P., Wielpütz, M. O., Siems, W., Gräber, S. Y., Mall, M. A., & Stahl, M. (2021). CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. Antioxidants, 10(3), 483. https://doi.org/10.3390/antiox10030483